HPM Web Site

  • HPM Web Site

Get Updates via E-mail

  • Enter your email address to automatically receive new posts to the FDA Law Blog via e-mail.

    Delivered by FeedBurner

 Subscribe in a reader




Disclaimer

  • FDA Law Blog is published for informational purposes only; it contains no legal advice whatsoever. Publication of FDA Law Blog does not create an attorney-client relationship. FDA Law Blog is the blog of Hyman, Phelps & McNamara, P.C. (“HPM”) and it is intended primarily for other attorneys and regulatory professionals. No part of FDA Law Blog --whether information, commentary, or other-- may be attributed to HPM's clients. Readers should be aware that HPM represents many companies in the food, drug, medical device, and health care industries, and therefore FDA Law Blog may occasionally report on news that relates to HPM clients. FDA Law Blog will always strive to be unbiased in its reporting. All information on FDA Law Blog should be double-checked for its accuracy and current applicability.

    Copyright 2011 Hyman, Phelps & McNamara, P.C.

Awards & Honors










« DC Circuit Rules for FDA in SEROQUEL Exclusivity Case; AstraZeneca Not Entitled to 3-Year Exclusivity | Main | HP&M Announces that Joseph Cormier has Joined the Firm as an Associate »

April 29, 2013

TrackBack

TrackBack URL for this entry:
http://www.typepad.com/services/trackback/6a00d8341d150c53ef01901bb2f7f7970b

Listed below are links to weblogs that reference Senate’s HELP Committee Releases Draft Compounding Legislation; Seeks Stakeholders’ Written Comments by May 3, 2013:

Comments

The comments to this entry are closed.